The therapeutic potential of novel aromatase inhibitors in breast cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/87843
Title:
The therapeutic potential of novel aromatase inhibitors in breast cancer.
Authors:
Taylor, Paul; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
For over 20 years, aromatase inhibitors have played a role in the treatment of breast cancer. However, until relatively recently, their utility has been limited by a lack of selectivity and significant toxicity. Several second and third generation aromatase inhibitors which are highly selective for the aromatase enzyme have reached clinical trials this decade. As a result of these initial studies, aromatase inhibitors are now established as second line agents in the treatment of postmenopausal women with advanced breast cancer. They are now under evaluation in several other settings, including adjuvant and neoadjuvant therapy, and as part of combination treatment in premenopausal women. This review focuses on recent and ongoing clinical trials and the effect these have had on the clinical use of aromatase inhibitors.
Affiliation:
CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK. ptaylor@picr.man.ac.uk
Citation:
The therapeutic potential of novel aromatase inhibitors in breast cancer. 1999, 8 (3):269-79 Expert Opin Investig Drugs
Journal:
Expert Opinion on Investigational Drugs
Issue Date:
Mar-1999
URI:
http://hdl.handle.net/10541/87843
DOI:
10.1517/13543784.8.3.269
PubMed ID:
15992077
Type:
Article
Language:
en
ISSN:
1744-7658
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorTaylor, Paulen
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2009-12-14T12:01:52Z-
dc.date.available2009-12-14T12:01:52Z-
dc.date.issued1999-03-
dc.identifier.citationThe therapeutic potential of novel aromatase inhibitors in breast cancer. 1999, 8 (3):269-79 Expert Opin Investig Drugsen
dc.identifier.issn1744-7658-
dc.identifier.pmid15992077-
dc.identifier.doi10.1517/13543784.8.3.269-
dc.identifier.urihttp://hdl.handle.net/10541/87843-
dc.description.abstractFor over 20 years, aromatase inhibitors have played a role in the treatment of breast cancer. However, until relatively recently, their utility has been limited by a lack of selectivity and significant toxicity. Several second and third generation aromatase inhibitors which are highly selective for the aromatase enzyme have reached clinical trials this decade. As a result of these initial studies, aromatase inhibitors are now established as second line agents in the treatment of postmenopausal women with advanced breast cancer. They are now under evaluation in several other settings, including adjuvant and neoadjuvant therapy, and as part of combination treatment in premenopausal women. This review focuses on recent and ongoing clinical trials and the effect these have had on the clinical use of aromatase inhibitors.en
dc.language.isoenen
dc.subjectAdjuvant Therapyen
dc.subjectBreast Canceren
dc.subjectAnastrozoleen
dc.subjectAromatase Inhibitorsen
dc.subjectNeoadjuvant Therapyen
dc.titleThe therapeutic potential of novel aromatase inhibitors in breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK. ptaylor@picr.man.ac.uken
dc.identifier.journalExpert Opinion on Investigational Drugsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.